149 related articles for article (PubMed ID: 32202792)
1.
Ferreira CA; Ehlerding EB; Rosenkrans ZT; Jiang D; Sun T; Aluicio-Sarduy E; Engle JW; Ni D; Cai W
Mol Pharm; 2020 May; 17(5):1697-1705. PubMed ID: 32202792
[TBL] [Abstract][Full Text] [Related]
2. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
3.
Ehlerding EB; Ferreira CA; Aluicio-Sarduy E; Jiang D; Lee HJ; Theuer CP; Engle JW; Cai W
Mol Pharm; 2018 Jul; 15(7):2606-2613. PubMed ID: 29787283
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
Int J Cancer; 2011 Feb; 128(4):920-6. PubMed ID: 20473899
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
Sugyo A; Tsuji AB; Sudo H; Okada M; Koizumi M; Satoh H; Kurosawa G; Kurosawa Y; Saga T
PLoS One; 2015; 10(4):e0123761. PubMed ID: 25893775
[TBL] [Abstract][Full Text] [Related]
6. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
7. PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site-Inhibited Factor VII.
Nielsen CH; Jeppesen TE; Kristensen LK; Jensen MM; El Ali HH; Madsen J; Wiinberg B; Petersen LC; Kjaer A
J Nucl Med; 2016 Jul; 57(7):1112-9. PubMed ID: 27013699
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.
Cardillo TM; Ying Z; Gold DV
Clin Cancer Res; 2001 Oct; 7(10):3186-92. PubMed ID: 11595713
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment of pancreatic cancer xenograft with
Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T; Higashi T
World J Gastroenterol; 2017 Nov; 23(42):7551-7562. PubMed ID: 29204055
[TBL] [Abstract][Full Text] [Related]
11. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
12. ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment.
Luo H; England CG; Goel S; Graves SA; Ai F; Liu B; Theuer CP; Wong HC; Nickles RJ; Cai W
Mol Pharm; 2017 May; 14(5):1646-1655. PubMed ID: 28292180
[TBL] [Abstract][Full Text] [Related]
13. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
[TBL] [Abstract][Full Text] [Related]
14. Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with
Sugyo A; Tsuji AB; Sudo H; Koizumi M; Ukai Y; Kurosawa G; Kurosawa Y; Saga T; Higashi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274301
[TBL] [Abstract][Full Text] [Related]
15. Quantitative PET Imaging of Tissue Factor Expression Using 18F-Labeled Active Site-Inhibited Factor VII.
Nielsen CH; Erlandsson M; Jeppesen TE; Jensen MM; Kristensen LK; Madsen J; Petersen LC; Kjaer A
J Nucl Med; 2016 Jan; 57(1):89-95. PubMed ID: 26383146
[TBL] [Abstract][Full Text] [Related]
16. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer.
Sabbah EN; Kadouche J; Ellison D; Finucane C; Decaudin D; Mather SJ
Nucl Med Biol; 2007 Apr; 34(3):293-304. PubMed ID: 17383579
[TBL] [Abstract][Full Text] [Related]
18. Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.
Luo H; England CG; Shi S; Graves SA; Hernandez R; Liu B; Theuer CP; Wong HC; Nickles RJ; Cai W
Clin Cancer Res; 2016 Aug; 22(15):3821-30. PubMed ID: 27026197
[TBL] [Abstract][Full Text] [Related]
19. Immuno-PET of tissue factor in pancreatic cancer.
Hong H; Zhang Y; Nayak TR; Engle JW; Wong HC; Liu B; Barnhart TE; Cai W
J Nucl Med; 2012 Nov; 53(11):1748-54. PubMed ID: 22988057
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
